Ameriprise Financial Inc. Has $12.94 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Ameriprise Financial Inc. lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,720,581 shares of the biotechnology company's stock after selling 51,920 shares during the period. Ameriprise Financial Inc. owned 0.83% of BioCryst Pharmaceuticals worth $12,939,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in shares of BioCryst Pharmaceuticals by 25.1% in the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 11,711 shares during the period. Raymond James Financial Inc. bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $80,000. Charles Schwab Investment Management Inc. grew its stake in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after buying an additional 91,998 shares during the last quarter. Finally, Choreo LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $106,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BCRX shares. JPMorgan Chase & Co. increased their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective on the stock. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective for the company. Finally, Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded up $0.32 during mid-day trading on Thursday, reaching $10.39. The company's stock had a trading volume of 5,656,407 shares, compared to its average volume of 3,028,898. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.92 and a twelve month high of $11.11. The company's fifty day simple moving average is $8.27 and its two-hundred day simple moving average is $8.00. The stock has a market cap of $2.17 billion, a P/E ratio of -17.03 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the previous year, the business posted $0.28 EPS. The business's quarterly revenue was up 40.8% on a year-over-year basis. Sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.